Expression of MAGE-A12 in oral squamous cell carcinoma

Disease Markers

Volumn 24, Issue 1, 2008, Pages 27-32

  Mollaoglu, Nur ^a,b   Vairaktaris, Eleftherios ^c   Nkenke, Emeka ^a   Neukam, Friedrich W ^a   Ries, Jutta ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GAZI UNIVERSITY   (Turkey)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diagnostic; MAGE A12 gene expression; Nested RT PCR; Oral squamous cell carcinoma; Therapy

Indexed keywords

MELANOMA ANTIGEN; MELANOMA ANTIGEN A12; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMOGRAPHY; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

EID: 36448996130     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/359840     Document Type: Article

References (26)

1. B. Sarcevic, G.C. Spagnoli, L. Terracciano, E. Schultz-Thater, M. Heberer, M. Gamulin, Z. Krajina, T. Oresic, R. Separovic and A. Juretic, Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma, Oncology 64 (2003), 443-449.
2. B. Schuler-Thurner, D. Dieckmann, P. Keikavoussi, A. Bender, C. Maczek, H. Jonuleit, C. Roder, I. Haendle, W. Leisgang, R. Dunbar, V. Cerundolo, P. von Den Driesch, J. Knop, EB. Brocker, A. Enk, E. Kampgen and G. Schuler, Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells, J Immunol 165 (2000), 3492-3496.
3. B.P. Van Der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, E.B. Van den, A. Knuth and T. Boon, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science 254 (1991), 1643-1647.
4. C. De Smet, C. Lurquin, B. Lethe, V. Martelange and T. Boon, DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter, Mol Cell Biol 19 (1999), 7327-7335.
5. D.L. Figueiredo, R.C. Mamede, R. Proto-Siqueira, L. Neder, W.A. Silva Jr and M.A. Zago, Expression of cancer testis antigens in head and neck squamous cell carcinomas, Head Neck 28 (2006), 614-619.
6. D.P. Slaughter, "Field cancerization" in oral stratified squamous epithelium: Clinical implications of multicentric origin, Cancer 6 (1953), 963-968.
7. E. De Plaen, K. Arden, C. Traversari, J.J. Gaforio, J.P. Szikora, C. De Smet, F. Brasseur, P. Van der Bruggen, B. Lethe, C. Lurquin et al., Structure, chromosomal localization, and expression of 12 genes of the MAGE family, Immunogenetics 40 (1994), 360-369.
8. E.S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T.G. Berger, K. Thielemanns, P. van der Bruggen and G. Schuler, Functional analysis of tumor-specific The cell responses detected in melanoma patients after dendritic cell-based immunotherapy, J Immunol 172 (2004), 1304-1310.
9. G. Luo, S. Huang, X. Xie, E. Stockert, Y.T. Chen, B. Kubuschok, M. Pfreundschuh, Expression of cancer-testis genes in human hepatocellular carcinomas, Cancer Immunity 2 (2002), 11-20.
10. J. Lin, L. Lin, D.G. Thomas, J.K. Greenson, T.J. Giordano, G.S. Robinson, R.A. Barve, F.A.Weishaar, J.M. Taylor, M.B. Orringer and D.G. Beer, Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants, Clin Cancer Res 17 (2004), 5708-5716.
11. J. Ries, S. Schultze-Mosgau, F. Neukam, E. Diebel and J. Wiltfang, Investigation of the expression of melanoma antigenencoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy, Int J Oncol 26 (2005), 817-824.
12. J.W. Park, T.K. Kwon, ich. Kim, S.S. Sohn, Y.S. Kim, C.I. Kim, O.S. Bae, K.S. Lee, K.D. Lee, C.S. Lee, H.K. Chang, B.K. Choe, S.Y. Ahn and C.H. Jeon, A new strategy for the diagnosis of MAGE-expressing cancers, J Immunol Methods 266 (2002), 79-86.
13. K.D. Hunter, E.K. Parkinson and P.R. Harrison, Profiling early head and neck cancer, Nat Rev Cancer 2 (2005), 127-135.
14. L. Heidecker, F. Brasseur, M. Probst-Kepper, M. Gueguen, T. Boon and B.J. Van den Eynde, Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12, J Immunol 164 (2000), 6041-6045.
15. M. Ding, R.J. Beck, C.J. Keller and R.G. Fenton, Cloning and analysis of MAGE-1-related genes, Biochem Biophys Res Commun 202 (1994), 549-555.
16. M. Eura, K. Ogi, K. Chikamatsu, K.D. Lee, K. Nakano, K. Masuyama, K. Itoh and T. Ishikawa, Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas, Int J Cancer 64 (1995), 304-308.
17. M. Otte, M. Zafrakas, L. Riethdorf, U. Pichlmeier, T. Loning, F. Janicke and K. Pantel, MAGE-A gene expression pattern in primary breast cancer, Cancer Res 15 (61) (2001), 6682-6687.
18. M.C. Panelli, M.P. Bettinotti, K. Lally, G.A. Ohnmacht, Y. Li, P. Robbins, A. Riker, S.A. Rosenberg and F.M. Marincola, A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12, J Immunol 164 (2000), 4382-4392.
19. M.J. Scanlan, A.J. Simpson and L.J. Old, The cancer/testis genes: review, standardization, and commentary, Cancer Immun 4 (2004), 1-15.
20. M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L.J. Old and Y.T. Chen, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, Immunol Rev 188 (2002), 22-32.
21. M.S. Park, J.W. Park, C.H. Jeon, K.D. Lee and H.K. Chang, Expression of melanoma antigen-encoding genes (MAGE) by common primers forMAGEA1toA6in colorectal carcinomas among Koreans, J Korean Med Sci 17 (2002), 497-501.
22. N. Sadanaga, H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, T. Akiyoshi and M. Mori, Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas, Clin Cancer Res 7 (2001), 2277-2284.
23. O. Bettendorf, J. Piffko and A. Bankfalvi, Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40 (2004), 110-119.
24. P. Kufer, A. Zippelius, R. Lutterbuse, I. Mecklenburg, T. Enzmann, A. Montag, D. Weckermann, B. Passlick, N. Prang, P. Reichardt, M. Dugas, M.W. Kollermann, K. Pantel and G. Riethmuller, Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease, Cancer Res 62 (2002), 251-261.
25. S.G. Patel and J.P. Shah, TNM staging of cancers of the head and neck: striving for uniformity among diversity, CA Cancer J Clin 55 (2005), 242-258.
26. X. Hao, Y. Shao, X. Ren, H. Liu, Q. Xu, H. Li, P. Zhang, X. An and B. Ren, Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients, J Cancer Res Clin Oncol 128 (2002), 507-515.